Key result
Immunosuppression for acute myocarditis lacks robust evidence and remains reserved for major clinical syndromes.
Why the study?
Treatment of myocarditis is often supportive, and the evidence for immunosuppression is scarce and debated.
This review summarizes current strategies for acute myocarditis, emphasizing that immunosuppression remains debated and is typically reserved for severe clinical presentations.
Answers are grounded in this paper and cite their sources.
Supports restrictive use of immunosuppression in acute myocarditis; leaves open need for randomized efficacy trials.
Myocarditis is an inflammatory disease of the myocardium characterized by a great heterogeneity of presentation and evolution. Treatment of myocarditis is often supportive, and the evidence for immunosuppression is scarce and debated. Conventional treatment is based on clinical presentation, ranging from conservative to advanced mechanical assist devices. In this setting, immunosuppression and immunomodulation therapies are mostly reserved for patients presenting with major clinical syndromes. In this review, we will summarize the current evidence and strategies for conventional and immunosuppressive treatments for patients presenting with acute myocarditis.
No takes yet. Share an insight, caveat, or question.
Ferone et al. (2024) conducted a review in Acute Myocarditis. Immunosuppression and immunomodulation therapies was evaluated. Immunosuppression and immunomodulation therapies for acute myocarditis are currently supported by scarce evidence and are mostly reserved for patients presenting with major clinical syndromes.
Synapse has enriched 10 related papers. Consider them for comparative context: